Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Jan 23:8:11.
doi: 10.1186/1746-1596-8-11.

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response

Elham O Hamed  1 , Hydi Ahmed, Osama B Sedeek, Abeer M Mohammed, Ali A Abd-Alla, Hazem M Abdel Ghaffar
Affiliations
Comparative Study

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response

Elham O Hamed et al. Diagn Pathol. .

Abstract

Background: Human epididymis protein 4 (HE4) is a novel and specific biomarker for ovarian cancer. The aim of this study is to evaluate a new tumor marker, HE4, in comparison with CA125 in diagnosis of epithelial ovarian cancer (EOC) and benign gynecological diseases.

Methods: CA125 and HE4 serum levels were determined in 30 patients with epithelial ovarian cancer (21 serous, 6 endometrioid and 3 mucinous tumors), 20 patients with benign gynecological diseases (8 patients with ovarian cyst, 5 patients with endometriosis, 4 patients with fibroid and 3 patients with pelvic inflammatory disease) and 20 healthy women. CA125 and HE4 cut-offs were 35 U/ml and 150 pmol/l, respectively.

Results: Serum HE4 and CA125 concentrations were significantly higher in the ovarian cancer patients compared with those seen in patients with benign disease or in the healthy controls (p = 0.001 and p < 0.001 respectively). In the receiver operating characteristic analysis (ROC), the area under the curve (AUC) values for HE4 was 0.96 (95% confidence interval, 0.9-1.0) and CA125 was 0.82 (95% confidence interval, 0.7-0.94). Compared to CA125, HE4 had higher sensitivity (90% vs. 83.3%), specificity (95% vs. 85%), PPV (93.1% vs. 80.7%) and NPV (92.7% vs. 87.2%), the combination of HE4 + CA125 the sensitivity and PPV reached 96.7% and 97% respectively.

Conclusion: Measuring serum HE4 concentrations along with CA125 concentrations may provide higher accuracy for detecting epithelial ovarian cancer.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1060413168685759.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ROC plot and AUC for CA125 and HE4 for patients with epithelial ovarian cancer and benign diseases.
Figure 2
Figure 2
Correlation (Spearman) between HE4 and CA125 on all groups.
Figure 3
Figure 3
HE4 and CA125 in the ovarian cancer group before and after treatment.
See this image and copyright information in PMC

References

    1. Rauh-Hain JA, Krivak TC, del Carmen MG, Olawaiye AB. Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol. 2011;4(1):15–21. - PMC - PubMed
    1. Lee KR, Tavassoli FA, Prat J, Dietel M, Gersell DJ, Karseladze AI, Hauptmann S, Rutgers J. In: pathology and genetics of tumours of the breast and female genital organs. Tavassoli FA, Devilee P, editor. Lyon: IARC Pres; 2003. WHO histological classification of tumours of the ovary (chapter 2) pp. 113–161.
    1. Nolen B, Marrangoni A, Velikokhatnaya L, Prosser D, Winans M, Gorelik E, Anna LA. A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol. 2009;112(1):47–54. - PMC - PubMed
    1. Kurman RJ, Shih I-M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42(7):918–931. - PMC - PubMed
    1. Hatice O, GoncaImir Y, Sema A, Meral C, Ersin T, Ali C. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol. 2012;7:124. - PMC - PubMed

Publication types

MeSH terms